Michael Thornton - ENDRA Life Chief Officer
| NDRA Stock | USD 4.30 0.27 6.70% |
Executive
Mr. Michael Thornton serves as Chief Technology Officer of the Company. Prior to joining ENDRA as Chief Technology Officer in 2007, Michael Thornton was a founder and President of Enhanced Vision Systems Corporationration, or EVS, a developer and supplier of medical imaging equipment to the pharmaceutical, biotech, and academic sectors. In 2002, EVS was acquired by General Electric Company and was integrated into the Functional and Molecular Imaging business unit of GE Medical Systems . Following the acquisition of EVS by GE Medical Systems, Mr. Thornton held a number of positions at GE Healthcare, including Sales Manager, Global Product Manager, and Site Leader. He was a member of the leadership team that expanded the preclinical imaging business to include computed tomography, optical, and positron emission tomography imaging technologies, with global market reach. He is also a founder of Volumetrics Medical Corporationration, a developer and manufacturer of quality assurance devices for diagnostic imaging. Prior to founding EVS, Mr. Thornton developed medical imaging related technologies at the Robarts Research Institute for which he obtained an MSc in Electrical Engineering from the University of Western Ontario since 2007.
| Age | 57 |
| Tenure | 18 years |
| Address | 3600 Green Court, Ann Arbor, MI, United States, 48105-1570 |
| Phone | 734 335 0468 |
| Web | https://endrainc.com |
Michael Thornton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Thornton against ENDRA Life stock is an integral part of due diligence when investing in ENDRA Life. Michael Thornton insider activity provides valuable insight into whether ENDRA Life is net buyers or sellers over its current business cycle. Note, ENDRA Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell ENDRA Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Thornton over a year ago Acquisition by Michael Thornton of 31960 shares of ENDRA Life subject to Rule 16b-3 | ||
Michael Thornton over a year ago Purchase by Michael Thornton of 15000 shares of ENDRA Life |
ENDRA Life Management Efficiency
The company has return on total asset (ROA) of (0.624) % which means that it has lost $0.624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4945) %, meaning that it created substantial loss on money invested by shareholders. ENDRA Life's management efficiency ratios could be used to measure how well ENDRA Life manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -1.41. In addition to that, Return On Capital Employed is expected to decline to -1.7. At present, ENDRA Life's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 6.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jean Muyl | DarioHealth Corp | N/A | |
| Mona Dean | DarioHealth Corp | N/A | |
| Omar MD | DarioHealth Corp | N/A | |
| Victoria Gavrilenko | Intelligent Bio Solutions | 41 | |
| Tomer BenKiki | DarioHealth Corp | 54 | |
| Rick Grubbs | Neuronetics | N/A | |
| Steven Nelson | DarioHealth Corp | 51 | |
| Jessica Olbricht | Biodesix | N/A | |
| David Holmes | Standard Biotools | N/A | |
| BS MB | Standard Biotools | 64 | |
| Steven Springmeyer | Biodesix | N/A | |
| William Bauta | bioAffinity Technologies Warran | N/A | |
| Jeremy Davis | Standard Biotools | N/A | |
| James MD | Biodesix | N/A | |
| Jeffrey Black | Standard Biotools | 55 | |
| Geoffrey MD | Neuronetics | 53 | |
| Xiaozhi Hu | Burning Rock Biotech | N/A | |
| Anna Turkington | Intelligent Bio Solutions | N/A | |
| Adam Taich | Standard Biotools | 48 | |
| Callistus Sequeira | Intelligent Bio Solutions | N/A | |
| Sara Grubbs | Neuronetics | N/A | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.62 |
ENDRA Life Sciences Leadership Team
Elected by the shareholders, the ENDRA Life's board of directors comprises two types of representatives: ENDRA Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ENDRA. The board's role is to monitor ENDRA Life's management team and ensure that shareholders' interests are well served. ENDRA Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ENDRA Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Thornton, Chief Officer | ||
| Renaud Maloberti, Chief Commercial Officer | ||
| Ziad Rouag, Head Affairs | ||
| Alexander Tokman, Acting Chairman | ||
| Jonathan Behr, CoFounder | ||
| Francois Michelon, Chairman of the Board, CEO | ||
| Richard Jacroux, Chief Officer | ||
| Irina Pestrikova, Senior Secretary | ||
| Steve Freeman, Human Leader |
ENDRA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ENDRA Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | (2.22 M) | ||||
| Shares Outstanding | 536.91 K | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 0.02 % | ||||
| Number Of Shares Shorted | 31.2 K | ||||
| Price To Earning | (0.93) X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (9.78 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in ENDRA Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ENDRA Life. If investors know ENDRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ENDRA Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ENDRA Life Sciences is measured differently than its book value, which is the value of ENDRA that is recorded on the company's balance sheet. Investors also form their own opinion of ENDRA Life's value that differs from its market value or its book value, called intrinsic value, which is ENDRA Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ENDRA Life's market value can be influenced by many factors that don't directly affect ENDRA Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ENDRA Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ENDRA Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ENDRA Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.